IMMP - Immutep Ltd ADR logo

Immutep Ltd ADR

IMMP

Immutep Ltd is a biotechnology company focused on developing LAG-3 related immunotherapies for cancer and autoimmune diseases. Its key product is eftilagimod alfa, aimed at activating the immune response, with several candidates in various clinical trials.

โš•๏ธ Healthcare NASDAQ Listed 2012 $ AUD
$1,000 invested 10 years ago โ†’$55today

Score Overview

1 Year
Score
Net Growth-26.27%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth182.31%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score2.8
Net Growth-159.41%
Net TrendNever
Net Income Consistencyโ€”
Rev Growth268.61%
Rev Trend80%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-25.08%
Net Trend20%
Net Income Consistency
Rev Growth81x
Rev Trend60%
Revenue Consistency
All Time
Score
Net Growth-289.01%
Net Trend29%
Net Income Consistency
Rev Growth9x
Rev Trend50%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Immutep Ltd ADR has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. IMMP does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 3.17โ€”
1 Year2025-10-22
$ 40.00-92.07%
5 Years2021-10-22
$ 86.20-96.32%
10 Years2016-10-21
$ 57.80-94.52%
All Time2012-04-17
$ 793.46-99.60%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in AUD

Year
2026$ 14M-$ 77M$ 68M
2025$ 5M-$ 61M$ 129M
2024$ 3M-$ 42M$ 181M
2023$ 3M-$ 39M$ 123M
2022$ 170.37K-$ 32M$ 79M
2021$ 3M-$ 29M$ 60M
2020$ 7M-$ 13M$ 26M
2019$ 139.78K-$ 16M$ 16M
2018$ 2M-$ 12M$ 23M
2017$ 4M-$ 9M$ 12M
2016$ 175.05K-$ 62M$ 20M
2015$ 2M-$ 32M$ 6M
2014$ 3M-$ 13M$ 23M
2013$ 4M-$ 15M$ 30M
IPO2012$ 1M-$ 19M$ 38M
IMMP - Immutep Ltd ADR logo

Immutep Ltd ADR fundamental performance

Between 2021 and 2026, revenue grew from $ 3M to $ 14M and net income went from -$ 29M to -$ 77M. Revenue increased in 4 of those 5 years; net income in 0.

Between 2016 and 2026, revenue grew from $ 175.05K to $ 14M and net income went from -$ 62M to -$ 77M. Revenue increased in 6 of those 10 years; net income in 2.

Immutep Ltd ADR currently holds a 5-year HDB Score of 2.8 out of 10. How the HDB Score is calculated.

Membership

Explore IMMP with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies